Right now the government wants to reschedule cannabis from a schedule 1 drug down to schedule 3, which is a half hearted move for the people. We must take cannabis completely off the controlled substances act, aka deschedule and remove federal control. Deschedule not Reschedule for true justice! 

In May, the government opened a public commenting period in the Federal Register regarding the proposed rescheduling of cannabis. This period resulted in the highest number of comments ever recorded in the history of the Federal Register, which has been in existence since July 26, 1935. According to data from the Drug Policy Alliance, nearly 70% of these comments supported descheduling cannabis, rather than rescheduling it.  This overwhelming public support reflects a significant shift in public opinion and highlights the growing demand for cannabis to be fully removed from restrictive regulatory categories.

Cannabis is widely used therapeutically and recreationally with no risk of fatal overdose, unlike alcohol, which can be deadly in excess yet remains easily accessible. Rescheduling cannabis hands control to big pharmaceutical corporations, prioritizing profits over people —just as they did during the opioid epidemic, when overprescription of addictive pills helped create the conditions for the ongoing fentanyl crisis. Descheduling keeps the plant in the hands of the people, preserving its intended use and accessibility. Keep reading to find out how we are going to make it happen

☆ Under Section 201 of the Controlled Substances Act (CSA) (21 U.S.C. § 811), proceedings to completely remove (decontrol), also known as deschedule, cannabis from the CSA may be initiated by individual citizens. ☆

 

Join our IG chat or FB chat for live discussions. If you want to get involved in a leadership role sign up on our FORM.

For Media contact or questions: Click Here

 

In light of the current proceedings around rescheduling, we must take bold action and petition for the complete descheduling of cannabis, rather than settling for a half-hearted move to Schedule 3. While the DEA is considering a rescheduling decision, it's crucial to understand that rescheduling would still maintain unnecessary restrictions and control, on cannabis use, research, and access. Schedule 3 gives access to Big Pharmaceutical corporations who can afford the federal licensing and compliances set forth by the DEA. As noted by the DEA themselves "if a cannabis-derived drug is rescheduled, it would still need to comply with the FDA's rules for approval, manufacturing, and distribution under the FDCA." The compliance process to get a cannabis-based drug approved and on the market can be very costly, often running into the tens of millions of dollars, particularly for drugs that need to go through the full clinical trial and regulatory approval process.

Pharmaceutical giants like Pfizer, Jazz Pharmaceuticals, and Constellation Brands are investing heavily in the cannabis industry in preparation for its potential rescheduling. Pfizer spent $6.7 billion to acquire Arena Pharmaceuticals, which focuses on cannabis-derived treatments, while Constellation Brands invested $4 billion in Canopy Growth Corporation, signaling their readiness to capitalize on the medical cannabis market as regulations shift.

We cannot let corporate interests, particularly from the pharmaceutical industry, dictate the future of cannabis policy. The pharmaceutical industry has historically lobbied against the legalization of cannabis, choosing profit over people by blocking access to natural alternatives. However, now they want in because of the growing market and proven medical benefits of cannabis. As public support for cannabis increases, pharmaceutical companies see an opportunity to profit by developing cannabis-based products. They aim to control this emerging market, ensuring they lead the production and sale of legal cannabis products, rather than allowing the community to thrive, including small farmers, mom-and-pop shops, and local businesses.

 

The people deserve better. They deserve access to affordable, effective treatments, not a system driven by profit at their expense. It's time to initiate the proceedings for descheduling and put people's health and well-being above corporate greed.

 

This is a movement powered by everyday individuals—people just like you—who, after becoming aware, are taking action and making this movement their own. By signing the petition, sharing the message, and advocating for change, we are channeling the collective voice of the people.

After signing, take the next step by taking action—share this petition, spread awareness, contact your representatives, organize town meetings, or inspire others to join the fight for change. Every effort counts in pushing this movement forward.

 

 

 

 

 

 

 

 

Are you actively involved in the cannabis community? 

Do you have a platform to help raise awareness? Whether it's through a podcast, radio show, daily livestreams, town meetings, events, a magazine, blog, journalism, or a significant social media following (on TikTok, X [formerly Twitter], Discord, Reddit, Instagram, Twitch, Bluesky, or others), you have the power to spark meaningful conversations about cannabis descheduling (not just rescheduling) and the importance of education. Join others in this effort to create a powerful wave of awareness and positive change.

For Podcasts, Livestreams, and Radio Shows

Dedicate an episode to cannabis reform. Bring on guests—experts, advocates, or community leaders—to share their perspectives and experiences. Use these platforms to discuss the importance of the petition and encourage listeners to take action by signing, sharing, and getting involved.

For Town Meetings and Events

Organize a local discussion or educational session focused on cannabis descheduling. Invite policymakers, medical professionals, and community advocates to speak. Use these events to distribute the petition, share key insights, and build local momentum for change.

For Print and Digital Media

Publish articles, op-eds, or opinion pieces that highlight the importance of cannabis descheduling. Focus on the social, medical, and economic benefits of reform, and emphasize the significance of the petition. Use these pieces to educate readers and urge them to take action.

For Social Media Platforms

Create engaging, short-form content on platforms like TikTok, Instagram, and X (formerly Twitter). Use graphics, videos, or infographics to explain the petition’s importance and provide clear calls to action. Encourage followers to sign and share the petition and to spread awareness in their own networks.

For Long-Form Content (YouTube, Blogs, Podcasts)

Dive deeper into the topic with thorough analysis and storytelling. Discuss the history of cannabis prohibition, the benefits of descheduling, and the impact on communities. Include a direct call to action for your audience to sign the petition, contact representatives, and educate others.

For Events and Public Gatherings

Use your presence at events to advocate for cannabis reform. Hand out informational materials, host a booth, or give a presentation that underscores the urgency of descheduling. Share the petition and encourage attendees to sign it on the spot.

A Universal Call to Action

Ask your audience: “What can you do to support the descheduling of cannabis?” Whether it’s signing and sharing the petition, creating educational content, contacting representatives, organizing events, or inspiring others to join the fight, every action matters. Together, we can make meaningful change happen.

 

IT'S TIME FOR CHANGE.

What We Demand:

We, the undersigned people alongside 27+ lawmakers, call upon all branches of the United States government—the Legislative, the Executive, and the Judicial Branch to work together and:

1. Deschedule Cannabis: Remove it entirely from the Controlled Substances Act to end federal criminalization.

2. Ensure Social and Criminal Justice:

Expunge records for non-violent cannabis offenses.

Release incarcerated individuals and reinvest in communities affected by cannabis prohibition.

3. Protect Against Discrimination:

Insurance: Prohibit insurers from charging higher premiums or denying coverage based on legal cannabis use.

Housing: Ban landlords from charging additional fees or denying rental applications for cannabis use or possession where it is legal.

Employment: Prevent employers from discriminating against workers for legal cannabis use outside of work hours.

Parental Rights: Safeguard parental custody and visitation rights from being impacted by legal cannabis use.

Banking and Financial Services: Ensure cannabis-related businesses and individuals have equitable access to banking and loans without predatory practices.

Education: Protect students from being denied scholarships, loans, or enrollment due to legal cannabis use.

Address Digital Discrimination: Demand equal treatment of cannabis content on platforms like Meta and ensure fair representation of cannabis businesses and advocates.

4. Recognize Cannabis as Medicine: Update federal policies to reflect scientific evidence of cannabis’s therapeutic potential and ensure it is treated like any other prescription or over-the-counter medicine.

5. Support Small Businesses and Farmers: Create grants, loans, and safeguards to protect local enterprises from monopolization and predatory practices.

6. Establish a National Plant Medicine Program: Promote equitable access to cannabis and other natural medicines for therapeutic use.

7. Create a Unified Regulatory Framework: Treat cannabis as a whole natural plant with diverse uses and regulate it as an agricultural commodity.

8. Establish the Office of Plant Medicine Oversight: Ensure transparent and safe regulation of natural medicines, including cannabis.

9. Promote Research and Innovation: Fund independent research on cannabis’s medical, industrial, and environmental applications.

10. Educate the Public: Launch nationwide campaigns to combat stigma, promote responsible use, and highlight the benefits of cannabis.

11. Advance Environmental Sustainability: Support sustainable farming practices for cannabis cultivation and explore hemp as a renewable material.

12. Ensure Consumer Protections: Develop clear standards for labeling, marketing, and product safety, prioritizing public health and transparency.

13. Facilitate Interstate and International Commerce: Develop policies to allow for fair trade and global standardization of cannabis products.

 

Cannabis, in all its forms, is a versatile and valuable plant with applications across medical, industrial, and recreational sectors. It is a single species with diverse uses, and the artificial division between hemp and marijuana creates unnecessary confusion, limiting its full potential. Recognizing cannabis as a unified plant enables us to harness its benefits for medical therapeutics, sustainable agriculture, energy production, and consumer goods. This approach promotes innovation, economic growth, and healthier consumer choices while ensuring equitable and responsible regulation.

 

☆ To determine if a substance should be descheduled, the CSA requires the following 8 factor analysis be considered ☆:

 

1.Potential for abuse

La Guardia Committee: The report debunked myths that cannabis causes significant behavioral issues or addiction, supporting the argument that cannabis has a lower potential for abuse compared to other controlled substances.

Shafer Commission: Highlighted the lack of evidence for widespread abuse or societal harm from cannabis, further undermining its Schedule I classification.

The DEA’s 2016 statement about marijuana having "high potential for abuse" was based on preclinical and clinical data showing reinforcing effects typical of substances that can be abused. However, they acknowledged that additional data was needed to fully assess marijuana's actual abuse potential. The argument here is that current data is insufficient to definitively classify marijuana as a high-risk substance. As cannabis research continues to evolve, its lower abuse potential compared to other substances becomes more apparent, supporting its descheduling.

In his 1988 ruling, Judge Francis Young concluded that marijuana is “one of the safest therapeutically active substances known to man.” This finding directly challenges the presumption that marijuana has a high potential for abuse. Young emphasized that marijuana does not carry the same risks of addiction or dependency as substances in higher schedules like heroin and cocaine. He stated that there is no indication that marijuana presents a high potential for abuse in any way comparable to the substances listed in Schedule I.

This ruling is pivotal in contesting the Schedule I classification of marijuana, which currently assumes a high potential for abuse. Young’s finding underscores that marijuana, when used appropriately, does not carry the same risks as other Schedule I drugs. This directly supports the argument for descheduling marijuana because its potential for abuse is consistently reported as being lower than that of other controlled substances.

Cannabis has a lower potential for abuse than alcohol and tobacco, yet it remains a Schedule I substance. Alcohol and tobacco are widely consumed, with significant abuse potential, but are regulated rather than scheduled. Over time, we have introduced measures such as drinking age laws and alcohol consumption regulations to address alcohol abuse. These regulatory frameworks could be similarly applied to cannabis to mitigate potential misuse while recognizing its relative safety compared to alcohol.

The CDC states: "A fatal overdose is unlikely."

The WHO notes: "There are no reports of fatal overdoses from cannabis in the epidemiological literature."

The NIDA concludes: "There has yet to be a drug overdose death solely attributed to cannabis."

These findings demonstrate that cannabis lacks the high abuse potential required for Schedule I, as abuse typically involves severe or fatal consequences, which are absent with cannabis.

 

2. Scientific evidence of effects

The HHS Patent (U.S. Patent 6630507), titled "Cannabinoids as Antioxidants and Neuroprotectants,"

The patent indirectly supports the argument that cannabis can improve public health by treating chronic illnesses and providing neuroprotective effects, reducing reliance on more harmful pharmaceuticals.

While the HHS analysis notes that Δ9-THC, the main psychoactive compound in marijuana, produces rewarding effects and can lead to euphoria and other pleasurable responses, it is important to recognize that these effects are mild and transient compared to highly addictive substances like opioids or alcohol. The addictive potential of cannabis is far lower than these drugs, with research showing that only a small percentage of users develop problematic use patterns. Moreover, the therapeutic benefits of cannabis—such as pain relief and anti-inflammatory effects—are well-documented and far outweigh the potential harms. More comprehensive studies will continue to provide a clearer understanding, but current evidence supports that cannabis should not be classified in the same category as more harmful substances.

In his 1988 decision, Judge Young found that marijuana’s pharmacological effects should not justify its classification as a Schedule I controlled substance. He emphasized that marijuana’s effects, while active, are not dangerous and should not lead to its classification among the most dangerous drugs like heroin or cocaine. Marijuana, as evidenced by both clinical and experimental studies, does not produce severe negative pharmacological effects when used appropriately, and its therapeutic benefits have been well-documented.

In contrast to substances like heroin or cocaine, marijuana has demonstrated a wide range of medical uses with minimal adverse effects. The growing body of scientific evidence supporting marijuana’s efficacy in treating conditions like chronic pain, anxiety, and nausea further solidifies the argument that its pharmacological profile does not warrant a Schedule I status. Thus, marijuana should be descheduled to better reflect its safety and medicinal value.

Cannabis has proven medicinal benefits, including pain relief and seizure management. Alcohol and tobacco lack medical value, with alcohol acting as a depressant and tobacco delivering highly addictive nicotine. Just as alcohol consumption has been regulated to reduce harm, cannabis can be safely regulated for both medicinal and recreational use, offering therapeutic benefits without the severe risks associated with alcohol and tobacco.

The CDC states: "A fatal overdose is unlikely."

The WHO notes: "There are no reports of fatal overdoses from cannabis in the epidemiological literature."

The NIDA concludes: "There has yet to be a drug overdose death solely attributed to cannabis."

These statements highlight the pharmacological safety of cannabis, showing that it does not have the dangerous effects associated with substances in Schedules I or II.

 

3. Current scientific knowledge

The vast and growing peer-reviewed literature on cannabis highlights its medical potential, safety profile, and minimal risks compared to other controlled substances. This evidence clearly supports the need to remove cannabis from the Controlled Substances Act entirely, rather than simply rescheduling it.

The HHS Patent (U.S. Patent 6630507), titled "Cannabinoids as Antioxidants and Neuroprotectants,"

The existence of this patent demonstrates that the federal government has recognized and protected intellectual property related to the medical benefits of cannabis. It aligns with the significant scientific advancements and thousands of peer-reviewed studies showing cannabis' therapeutic properties.

Cannabis research is expanding and highlights its therapeutic potential. Alcohol and tobacco are well-studied but primarily known for their harmful effects on health. Over time, we've learned how to reduce the dangers of alcohol use (e.g., through education, responsible drinking, and drinking age laws), and similar public health measures could be applied to cannabis to minimize risks while promoting its medicinal use.

The CDC states: "A fatal overdose is unlikely."

The WHO notes: "There are no reports of fatal overdoses from cannabis in the epidemiological literature."

The NIDA concludes: "There has yet to be a drug overdose death solely attributed to cannabis."

Decades of research confirm that cannabis does not cause fatal overdoses, providing strong evidence that its risks have been overstated.

 

4. History and current pattern of abuse

La Guardia Committee: Demonstrated that earlier claims about cannabis-related harm were unfounded, contributing to a more accurate understanding of its historical use and societal impact.

Shafer Commission: Analyzed usage trends and confirmed that cannabis was not a major public health concern, supporting the idea that abuse patterns do not warrant stringent controls.

Anslinger, the first commissioner of the Federal Bureau of Narcotics, propagated misinformation about cannabis, linking it to violence and insanity without scientific backing. This campaign shaped public perception and led to the Marihuana Tax Act of 1937, despite contrary evidence from the La Guardia Committee Report (1944), which debunked such claims.

Anslinger’s actions distorted the true historical patterns of cannabis use, leading to the perpetuation of unfounded fears rather than evidence-based policies.

While marijuana remains the most widely used illicit drug, it is important to note that its abuse potential is far lower than substances like heroin, cocaine, or opioids. Marijuana's non-medical use is indeed widespread, but compared to alcohol, which has a much higher usage rate and is linked to far more harmful effects, cannabis is far less harmful. The majority of marijuana users do not develop dependence or experience significant negative consequences. The widespread use also reflects increasing medical acceptance, as marijuana becomes more accessible for legitimate therapeutic use. Therefore, the concern around abuse should not overshadow its therapeutic benefits or support continued restrictions that limit access to medical marijuana for those who can benefit.

Judge Young’s ruling in 1988 also emphasized that marijuana, compared to substances like heroin and cocaine, presents far less of a public health risk. He found no evidence to suggest that marijuana would result in significant health issues when used appropriately, especially when compared to more harmful controlled substances. Studies have since supported this conclusion, showing that marijuana’s harm to public health is minimal, with no known fatal overdose rate.

Young’s assessment also aligns with data showing that marijuana-related public health issues, such as hospitalizations or deaths, are far lower than those linked to other illicit substances like opioids. This finding strongly supports the argument for descheduling marijuana, as its risk to public health is significantly lower than that of drugs currently classified in higher schedules.

Cannabis use is widespread but less harmful than alcohol and tobacco. Alcohol is linked to violence, accidents, and impaired judgment, while tobacco is the leading cause of preventable death. Through responsible drinking campaigns and policies, we've worked to reduce alcohol abuse, suggesting that similar education and regulation for cannabis could further reduce misuse and harm.

The CDC states: "A fatal overdose is unlikely."

The WHO notes: "There are no reports of fatal overdoses from cannabis in the epidemiological literature."

The NIDA concludes: "There has yet to be a drug overdose death solely attributed to cannabis."

These patterns of safe use, with no fatalities reported even in heavy users, contrast sharply with substances that cause frequent overdose deaths and belong in Schedule I.

 

5. Scope, duration, and significance of abuse

Shafer Commission: Concluded that cannabis use did not significantly harm public health or lead to widespread abuse, which directly addresses this factor.

President Nixon ignored the recommendations of the Shafer Commission (1972), which concluded that cannabis should not be classified as a Schedule I substance and recommended decriminalization. Instead, Nixon used the "War on Drugs" as a political tool to target certain demographics and suppress dissent, as confirmed by Nixon aide John Ehrlichman in later years.

Nixon’s manipulation exaggerated the societal impact of cannabis use, inflating its perceived abuse potential and significance to justify harsh policies.

Cannabis does not pose a major public health risk compared to legal substances like alcohol.

HHS's analysis shows that marijuana’s abuse consequences are less severe than those of substances like alcohol, heroin, and cocaine, all of which are less regulated or more heavily restricted. Despite marijuana’s prevalence, the negative outcomes, including substance use disorder (SUD), are not as widespread or severe as with other substances. Additionally, the increase in daily marijuana use reported in the past years does not correlate with a corresponding increase in addiction rates or fatalities, reinforcing the argument that marijuana does not present the same societal harm as other controlled substances.

Judge Francis Young’s 1988 ruling made it clear that marijuana does not have a high potential for physical or psychological dependence, especially when compared to substances like alcohol, opioids, or cocaine. He emphasized that marijuana’s potential for dependence is relatively mild, and withdrawal symptoms are far less severe than those associated with more dangerous drugs. Marijuana is widely considered to have a lower risk of addiction, and users are generally able to regulate their consumption without developing compulsive patterns of use.

This assessment stands in stark contrast to the characterization of marijuana as a highly addictive substance. The evidence surrounding marijuana use supports that the risk of addiction is much lower than that of substances currently listed in Schedule I. As such, marijuana should not be classified as a Schedule I substance based on the false premise of a high dependency risk, further supporting its descheduling.

Cannabis abuse has a lower societal impact than alcohol and tobacco, which contribute to significant health and economic burdens due to addiction and disease. The historical lessons from alcohol regulation—like taxation, age restrictions, and public health campaigns—can be applied to cannabis to minimize societal harm and ensure that cannabis use remains safe and controlled.

The CDC states: "A fatal overdose is unlikely."

The WHO notes: "There are no reports of fatal overdoses from cannabis in the epidemiological literature."

The NIDA concludes: "There has yet to be a drug overdose death solely attributed to cannabis."

These findings demonstrate that cannabis does not exhibit abuse patterns or overdose risks that justify its severe regulation.

 

6. Public health risk

La Guardia Committee: Found no evidence that cannabis posed significant health risks, challenging the justification for its strict scheduling.

Shafer Commission: Emphasized that cannabis does not pose a major threat to public safety or health, aligning with evidence from contemporary studies.

The HHS Patent (U.S. Patent 6630507), titled "Cannabinoids as Antioxidants and Neuroprotectants,"

The patent indirectly supports the argument that cannabis can improve public health by treating chronic illnesses and providing neuroprotective effects, reducing reliance on more harmful pharmaceuticals.

Both Anslinger and Nixon disregarded scientific findings, choosing instead to emphasize the supposed public health risks of cannabis based on political motives rather than actual evidence. Their actions contributed to decades of misinformation and restrictive policies that have stifled research and access.

Cannabis is far safer than substances like tobacco and alcohol.

While HHS and DEA highlight the risks associated with marijuana, including impaired driving and chronic use consequences, the relative harm from marijuana is significantly lower compared to substances like heroin or cocaine. Epidemiological data show that overdose deaths and hospitalizations related to marijuana are much rarer than with these more harmful substances. Additionally, marijuana use does not typically result in the same severity of physical dependence as other controlled substances. Although data on driving impairment exists, its overall impact on public health is far less severe than alcohol or other drugs with similar risks.

Judge Young’s ruling in 1988 noted that marijuana had established medical uses, particularly for pain relief and as an appetite stimulant. At the time, Young acknowledged that marijuana had therapeutic uses that were supported by scientific evidence, and these uses have only grown in recognition in recent years. As more states have legalized medical marijuana, and more research has been conducted, the evidence for marijuana’s efficacy in treating conditions such as chronic pain, nausea, and certain neurological disorders has become even more robust.

This aligns with the increasing body of clinical evidence, which has demonstrated that marijuana is an effective treatment option for a variety of medical conditions. The growing acceptance of marijuana as a legitimate medicine directly contradicts its classification as a Schedule I substance, which asserts that it has no accepted medical use. This makes the case for descheduling marijuana even more compelling.

Cannabis poses relatively minor public health risks compared to alcohol, which causes accidents, liver damage, and long-term addiction, and tobacco, which leads to cancer and cardiovascular disease. Just as alcohol-related public health issues were mitigated through policy and research (e.g., alcohol education and breathalyzer technology), cannabis can be regulated in a way that minimizes risks and promotes public safety.

The CDC states: "A fatal overdose is unlikely."

The WHO notes: "There are no reports of fatal overdoses from cannabis in the epidemiological literature."

The NIDA concludes: "There has yet to be a drug overdose death solely attributed to cannabis."

These statements show that cannabis presents minimal risk to public health, undermining its classification as a dangerous Schedule I substance.

 

7. Psychic or physiological dependence

Cannabis is widely recognized as having a low potential for dependence compared to other substances, especially those classified in Schedule I. According to the National Institute on Drug Abuse (NIDA), while some individuals may develop mild cannabis use disorder, this is far less severe than addiction to substances like opioids, alcohol, or tobacco. Cannabis has not been shown to cause the same level of physical dependence or withdrawal symptoms as substances currently in Schedule I or II, such as heroin or cocaine.

Unlike substances that lead to significant withdrawal symptoms and physiological dependence (e.g., alcohol, opioids), cannabis does not carry a significant risk of addiction. It has far fewer harmful long-term effects, with users rarely experiencing the kind of psychological or physiological dependence seen in other controlled substances.

HHS and DEA emphasize that chronic use of marijuana can lead to psychic and physical dependence, but these symptoms are typically mild compared to other substances like alcohol or opioids. The severity of dependence increases with prolonged exposure, yet the overall risk is far less significant than for alcohol or heroin, which are far more addictive. Research also indicates that the diagnosis of Cannabis Use Disorder (CUD) may be overstated and not reflective of the broader population.

Cannabis has a moderate risk of dependence, with mild withdrawal symptoms. Alcohol and tobacco have much higher dependence liabilities, with severe withdrawal effects for alcohol and extreme addictiveness for tobacco. Overcoming alcohol and tobacco dependence has involved a combination of regulation, medical treatment, and education. A similar approach for cannabis could reduce dependency risks while making the substance more accessible for medicinal use.

 

8. Immediate precursor status

Cannabis is not an immediate precursor to any other controlled substance. It does not serve as a gateway drug or precursor for the creation of more dangerous or addictive substances, as is often claimed by opponents of cannabis legalization. The notion that cannabis leads to harder drug use has been repeatedly debunked by scientific research. Studies consistently show that cannabis use does not significantly increase the likelihood of transitioning to substances like heroin or cocaine.

The idea of cannabis as a “gateway drug” has been thoroughly discredited. The National Institute on Drug Abuse (NIDA) and other reputable research institutions have found no conclusive evidence that cannabis use leads directly to the use of more harmful substances. As such, cannabis does not function as a precursor to other controlled substances, making its current Schedule I status completely unjustifiable.

Both HHS and DEA have concluded that marijuana is not an immediate precursor of another controlled substance, which means it does not directly lead to the creation of more dangerous drugs like heroin or cocaine. This finding underlines marijuana’s unique status in the broader drug landscape, supporting its descheduling based on its lack of direct relation to substances with higher abuse and harm potential.

 

A Timeline of Evidence Ignored by Prohibitionists

1930s: The Era of Yellow Journalism and Reefer Madness

William Randolph Hearst used sensationalist headlines to demonize cannabis, motivated by economic interests in timber and paper.

"Reefer Madness" Propaganda stigmatized cannabis, framing it as a drug linked to violence, insanity, and racial minorities.

1944: LaGuardia Committee Report

Debunked myths spread by "Reefer Madness," concluding cannabis was not addictive, did not cause insanity, and had no link to violent behavior.

1972: Nixon and the Shafer Commission:

President Nixon ignored the Shafer Commission Report, which recommended decriminalizing cannabis based on its lack of significant public harm.

1994: Nixon Tapes and Ehrlichman’s Admission. Administration officials admitted the "War on Drugs" was a tool to target political dissenters and minorities. Nixon dehumanized drug users because it was in his political interest to do so.

The White House tapes recorded Nixon saying, “There’s a funny thing, every one of the bastards who is out there to legalize marijuana is Jewish.” Nixon added, “What the Christ is the matter with the Jews.” Like a lot of things that Nixon said, his comments about Jews and marijuana had little if any basis in fact.

“Let me tell you, I know nothing about marijuana,” Nixon said at one point. “I know that it’s not particularly dangerous, and most of the kids are for legalizing it. But on the other hand, it’s the wrong signal at this time.”

“You want to know what this was really all about? The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and Black people. You understand what I’m saying? We knew we couldn’t make it illegal to be either against the war or Black, but by getting the public to associate the hippies with marijuana and Blacks with heroin, and then criminalizing both heavily, we could disrupt those communities. We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news. Did we know we were lying about the drugs? Of course we did." Mr. Ehrlichman said in an interview published by Harper’s Magazine

1988: Judge Francis Young's DEA Ruling

The DEA’s own administrative law judge declared cannabis "one of the safest therapeutically active substances known to man," 

1999: HHS Patent #6630507

The Department of Health and Human Services (HHS) patented cannabinoids for their neuroprotective and antioxidant properties, recognizing their medicinal potential while maintaining federal prohibition.